SKL2001 (Synonyms: Wnt Agonist II) |
| Katalog-Nr.GC16382 |
SKL2001 ist ein Agonist des Wnt/β-Catenin-Signalwegs mit Anti-Krebs-AktivitÄt. SKL2001 stabilisiert intrazellulÄres β-Catenin durch Unterbrechung der Axin/β-Catenin-Wechselwirkung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 909089-13-0
Sample solution is provided at 25 µL, 10mM.
SKL2001 is an agonist of the Wnt/β-catenin pathway. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction, and can be applied to regulate mesenchymal stem cell differentiation[1].
SKL2001 (5, 10, and 30μM; 3d) consistently induced the accumulation of intracellular β-catenin and inhibited the expression of C/EBPα and PPARγ. The exposure of 3T3-L1 and ST2 cells to SKL2001 resulted in a concentration-dependent decrease in lipid droplet accumulation in response to insulin[1]. SKL2001 (10, 30μM; 15h) upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45[1].Treatment of ECs with SKL2001 at 30μM for 12h induced the expressions of MALAT1, ZO-1 and Occludin[2].
SKL2001 (6mg/kg; ip; 7d) treatment results in a decrease in the permeability of the aortic wall of the mice[2].In the doxorubicin mouse model, SKL2001 (4mg/kg; ip; 7d) stimulated rCFs to activate the Wnt/β-catenin pathway, inducing cardiac dysfunction and myocardial fibrosis in mice[3].
References:
[1]. Gwak J, Hwang S G, Park H S, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation[J]. Cell research, 2012, 22(1): 237-247.
[2]. Yang F, Zhang Y, Zhu J, et al. Laminar flow protects vascular endothelial tight junctions and barrier function via maintaining the expression of long non-coding RNA MALAT1[J]. Frontiers in Bioengineering and Biotechnology, 2020, 8: 647.
[3]. Yuan M, Shi H, Wang B, et al. Targeting SOCS2 alleviates myocardial fibrosis by reducing nuclear translocation of β-catenin[J]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2024, 1871(7): 119804.
| Cell experiment [1]: | |
|
Cell lines |
3T3-L1 and ST2 cells |
|
Preparation Method |
SKL2001 (5, 10, and 30μM) was administered to cells during adipocyte differentiation for 3 days. The total proteins were prepared and subjected to western blotting with anti-β-catenin, anti-PPARγ and anti-C/EBPα antibodies. |
|
Reaction Conditions |
5, 10, and 30μM; 3d |
|
Applications |
SKL2001 consistently induced the accumulation of intracellular β-catenin and inhibited the expression of C/EBPα and PPARγ. The exposure of 3T3-L1 and ST2 cells to SKL2001 resulted in a concentration-dependent decrease in lipid droplet accumulation. |
| Animal experiment [2]: | |
|
Animal models |
Arterial Endothelial Barrier Model |
|
Preparation Method |
Mice were injected intraperitoneally with SKL2001 (6mg/kg in 100μL of DMSO), XAV939 (4mg/kg in 100μL of DMSO) or DMSO (100μL) daily for 7 days. The arterial endothelial permeability to Evans blue dye was assessed. |
|
Dosage form |
6mg/kg; ip; 7d |
|
Applications |
Aortic wall permeability to Evans blue was reduced in SKL2001-treated mice. |
|
References: |
|
| Cas No. | 909089-13-0 | SDF | |
| Überlieferungen | Wnt Agonist II | ||
| Chemical Name | N-(3-(1H-imidazol-1-yl)propyl)-5-(furan-2-yl)isoxazole-3-carboxamide | ||
| Canonical SMILES | O=C(C1=NOC(C2=CC=CO2)=C1)NCCCN3C=CN=C3 | ||
| Formula | C14H14N4O3 | M.Wt | 286.29 |
| Löslichkeit | DMF: 25 mg/ml,DMSO: 25 mg/ml,Ethanol: 25 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.493 mL | 17.4648 mL | 34.9296 mL |
| 5 mM | 0.6986 mL | 3.493 mL | 6.9859 mL |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.493 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *